.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,372,432

« Back to Dashboard

Claims for Patent: 8,372,432

Title:Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
Inventor(s): Han; Chien-Hsuan (Sunnyvale, CA), Hou; Sui Yuen Eddie (Foster City, CA), Reid; Monica L. (San Mateo, CA)
Assignee: Depomed, Inc. (Newark, CA)
Application Number:12/644,444
Patent Claims: 1. A dosage form for extended release of an opioid and acetaminophen, comprising: an extended release (ER) portion comprising a polymer matrix with a first dose of acetaminophen and a first dose of an opioid selected from oxycodone and hydrocodone dispersed therein, said polymer matrix comprised of between about 20-60 weight percent poly(ethylene oxide) having a molecular weight of between about 900,000 Daltons to 4,000,000 Daltons, wherein said matrix swells upon imbibition of fluid to a size sufficient to promote gastric retention in a gastrointestinal tract of a subject, said first dose of acetaminophen released from the dosage form through erosion of the polymer matrix, and said first doses of opioid and acetaminophen controllably-released from the dosage form such that substantially all of each of the first doses is released within about ten hours, when measured in an in vitro disintegration test using a USP type II apparatus at 37.degree. C. in 0.1N HCI.

2. The dosage form of claim 1, wherein the first dose of acetaminophen is about 100 mg to about 600 mg.

3. The dosage form of claim 1, wherein the opioid is oxycodone.

4. The dosage form of claim 1, wherein the poly(ethylene oxide) has a molecular weight of about 900,000 Daltons.

5. The dosage form of claim 1, wherein the poly(ethylene oxide) is present in an amount ranging from about 35 wt % to about 50 wt % of the extended release portion.

6. The dosage form of claim 1, wherein the extended release portion comprises particles of the opioid granulated with a binder and a filler.

7. The dosage form of claim 6, wherein the particles have an average particle size greater than about 20 microns and less than about 2000 microns.

8. The dosage form of claim 1, further comprising an immediate release portion comprising a second dose of acetaminophen and a second dose of the opioid, said immediate release portion in contact with said extended release portion.

9. The dosage form of claim 8, wherein the second dose of acetaminophen is approximately 175 mg to 240 mg.

10. The dosage form of claim 8, wherein the immediate release portion of the dosage form and the extended release portion of the dosage form comprise a bilayer tablet.

11. The dosage form of claim 10, wherein said tablet has a hardness of about 12 Kp to about 20 Kp.

12. The dosage form of claim 10, wherein said tablet has a friability of less than about 1.0%.

13. The dosage form of claim 10, wherein upon administration of the tablet to the subject, the ER portion imbibes fluid and swells to a size between about 120% to about 140% of the size of the dosage form size prior to administration within 1 hour after administration.

14. The dosage form of claim 10, wherein between about 40% to about 60% of the acetaminophen and between about 50% to about 70% of the opioid are released within about 1 hour in an in vitro disintegration test.

15. A method for treating a subject suffering from pain, comprising orally administering to said subject the dosage form of claim 1.

16. The method of claim 15, wherein said administering comprises administering twice in a 24-hour period, and wherein said administering is with a meal.

17. The dosage form of claim 1, further comprising a chelating agent, wherein said chelating agent is present in the ER portion at an amount ranging from about 0.01 wt % to about 0.1 wt %.

18. The dosage form of claim 1, further comprising an antioxidant.

19. The dosage form of claim 18, wherein said antioxidant is present in the ER portion at an amount ranging from about 0.05 wt % to about 0.35 wt%.

20. The dosage form of claim 1, wherein the first dose of opioid is approximately about 5 mg to about 60 mg.

21. The dosage form of claim 1, wherein the first dose of opioid ranges from about 5 mg to about 40 mg.

22. The dosage form of claim 1, wherein the poly(ethylene oxide) is present in the ER portion in an amount ranging from about 25 wt % to about 55 wt %.

23. The dosage form of claim 1, wherein the poly(ethylene oxide) has a molecular weight of about 900,000 or about 1,000,000 daltons and wherein the polymer is present in the ER portion in an amount ranging from about 30 wt % to about 50 wt %.

24. The dosage form of claim 1, wherein release approaching zero-order of the opioid is observed over a period of approximately six hours.

25. The dosage form of claim 1, wherein the polymer matrix is a monolithic polymer matrix in which said first doses are dispersed, and wherein said first doses are therapeutically effective doses.

26. The dosage form of claim 1, wherein the opioid is hydrocodone.

27. The dosage form of claim 1, wherein the poly(ethylene oxide) has a molecular weight of between about 900,000 daltons to about 2,000,000 daltons.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc